GH:
The current live price is 85.41, showing a percentage change of -1.21%.
Support and Resistance Levels
The current support levels are 85.5, 84.11, and 83.415, while the resistance levels are 87.585, 88.28, and 89.67. The pivot point is at 86.195.
Indicators
The RSI is at 65.73, indicating upward momentum, while the ATR is 0.38738, showing low volatility. The ADX is at 42.314, suggesting a strong trend. The Parabolic SAR is currently at 87.10013, indicating a bearish signal since it is above the price. The 50-day SMA is 86.50962, showing a downtrend.
Market Sentiment
The price is below the pivot point (86.195), and indicators suggest a bearish trend.
GH Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Guardant Health Inc. (NASDAQ: GH) is a pioneering precision oncology company founded in 2012, headquartered in Redwood City, California. The company focuses on transforming cancer care through its advanced blood-based genomic tests. Guardant's proprietary technology enables the detection of cancer DNA in the bloodstream, facilitating early diagnosis, treatment selection, and monitoring of cancer therapy responses. With a commitment to improving patient outcomes, Guardant Health has positioned itself at the forefront of liquid biopsy innovation, serving both healthcare providers and patients globally.
Market Position
Guardant Health holds a prominent position in the precision oncology market, recognized for its flagship product, Guardant360, a comprehensive liquid biopsy test that profiles genomic alterations in solid tumors. With a growing demand for non-invasive cancer diagnostics and management solutions, Guardant has successfully established partnerships with leading pharmaceutical companies and academic institutions. The company's strong emphasis on research and development further solidifies its market leadership, allowing it to expand its product offerings, including GuardantOMNI and Guardant Reveal, catering to diverse diagnostic needs in oncology.
Key Financial and Industry Highlights
As of October 2023, Guardant Health has demonstrated robust financial performance, with significant revenue growth driven by increasing adoption of its liquid biopsy tests. The company reported a revenue of $147.6 million in 2022, marking a 43% increase from the previous year. This growth trajectory is backed by a growing customer base and expanding market presence, as Guardant continues to penetrate international markets and enhance its product pipeline. Industry trends indicate a rising preference for liquid biopsies among oncologists and patients, driven by their non-invasive nature and the ability to provide real-time insights into tumor dynamics. Guardant Health's innovative solutions position it well to capitalize on these trends, directly impacting its future growth and market expansion.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
